Literature DB >> 19920874

Gadolinium-associated nephrogenic systemic fibrosis.

June M McKoy1, Anne Laumann, Athena Samaras, Mario Lacouture, Dennis West, Dennis Raisch, Eniola Obadina, Olukemi Fajolu, Lauren Reilly, Charles L Bennett.   

Abstract

The authors explain why physicians should refrain from ordering MRIs for patients with renal dysfunction unless the test is essential to provide diagnostic information. A possibly class-wide toxicity from the contrast agent gadolinium has been reported.

Entities:  

Year:  2008        PMID： 19920874      PMCID： PMC2777717          DOI： 10.1016/s1548-5315(11)70463-6

Source DB:  PubMed          Journal:  Community Oncol        ISSN： 1548-5315


  2 in total

Review 1.  Nephrogenic fibrosing dermopathy: the first 6 years.

Authors:  Shawn E Cowper
Journal:  Curr Opin Rheumatol       Date:  2003-11       Impact factor: 5.006

2.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?

Authors:  Thomas Grobner
Journal:  Nephrol Dial Transplant       Date:  2006-01-23       Impact factor: 5.992
  2 in total
  1 in total

Review 1.  Results from the first decade of research conducted by the Research on Adverse Drug Events and Reports (RADAR) project.

Authors:  June M McKoy; Matthew J Fisher; D Mark Courtney; Dennis W Raisch; Beatrice J Edwards; Marc H Scheetz; Steven M Belknap; Steven M Trifilio; Athena T Samaras; Dustin B Liebling; Beatrice Nardone; Katrina Marie Tulas; Dennis P West
Journal:  Drug Saf       Date:  2013-05       Impact factor: 5.606
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.